Click Therapeutics, Inc. and UK-based pharmaceutical company Indivior plc announced a collaboration to develop and commercialize a prescription digital therapeutics for treating substance use disorders, starting with opioid use disorder.
Under the terms of the deal, Click Therapeutics will receive upfront license and early development payments to develop the mobile app, dubbed CT-102. The company is also eligible to receive...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?